Great speakers at this symposium - 22 April 2026 at LSHTM. Join online or in person (email if in person) to hear great talks at the cutting edge of Inequalities in infectious disease dynamics. www.lshtm.ac.uk/newsevents/e...
Lenacapavir is a great HIV prevention drug and I really hope Gilead agree to MSF's request to sell it to them so they can provide it to those who patently need it most.
Some thoughts here:
jackwgoodall.github.io/infection_up...
#IDsky #globalhealth
This is indescribably sad development in an already appalling man-made humanitarian crisis
PLEASE SHARE. PhD Opportunity with me, Ben Raymond and Jan Engelstaedter and Andrew Letten at University of Queensland.
Experimentally testing mechanisms of how temperature may change selection and spread of AMR in E. coli. Coupled with some advanced modelling and sequencing.
🧪🦠 #microsky
1/ Announcing the IDD Connect Series! #IDsky #EpiSky 🧪
❓Interested in hearing from infectious disease dynamics organizations from different regions?
📣 IDD Connect is a monthly initiative to bring together the infectious disease dynamics global community
📧 Join GSIDD mailing list for event links👇
Yes I've been really enjoying those - like you say their focus seems to be on clinical trials and trial methodology. I'll add a link to them in the resources section
And if you don't work in ID - firstly I'm very sorry to hear that - but if you like the journal feed and would like to replicate it for your speciality, its open sourced on my github and I would be happy to walk you through it
A few colleagues have kindly agreed to help write the blog updates - but the more the merrier - if you would like that contribute that would be amazing - please get in touch.
Please also let me know if there are ways it could be improved or journals/resources that should be added.
I've made a website for clinically relevant infection research:
jackwgoodall.github.io/infection_up...
It's in its early days but it has summaries of recent infection papers that caught my eye, an OpenAlex feed of recent infection papers from high impact journal and a resources section
#IDSky
So this interview lasted 2 hours so this “you’re scaring me” part might seem like an overreaction or fearmongering to someone without that context.
There’s a lot of evidence to support my hypothesis that a potential H5N1 pandemic would be worse than COVID.
ID gurus - what are your thoughts on the optimal tx for S. pneumo meningitis that is pansensitive?
ESCMID guidelines: PCN or amp/amox
IDSA guidelines: PCN
NICE guidelines: Ceftriaxone
PCN: lower risk of CDiff, antimicrobial stewardship rizz
Ceftriaxone: fewer infusions, pt already on this
#IDsky
The danger of course is that this nuance is lost on whoever orders the test and TB gets erroneously “ruled out”. This seems to be more of an issue of education and result presentation that an intrinsic fault in the test
I’ve often wondered about whether we are too dogmatic about this in ID. There are lots of tests (eg all of the physical exam!) that have comparably bad performance characteristics. We don’t pretend they are 100 sens/spec but understand their limitations and do a good bit of Bayesian inference
Great summary Alasdair. I suspect asymptotic carriage is less of a phenomenon in adults - but still happens.
Some of my colleagues would argue though that the specificity is near enough 100% in adults that the diagnosis is made when you get a +ve (NPS) PCR. Anyone got thoughts (or a reference!)?
Our @shorten2trial.bsky.social aims to confirm that 7-day treatments are superior to 14-day courses for uncomplicated P. aeruginosa BSI.
Check out our full protocol 👉🏻 journals.plos.org/plosone/arti...
#AMSsky #IDSky
💉 How do we optimise the neutralising antibody responses of HSCT/CAR-T recipients following COVID vaccination? We found ChAdOx1-S recipients were EIGHT times more likely to have neutralising antibodies than those receiving mRNA vaccines in our new paper! Read more --> doi.org/10.1111/bjh....
Ah amazing - glad you liked it! Please do feel free to add to it
BIA now on blue sky 👏 - and please consider applying for our ECR and small project grants!
A global health starter back would be a great public service. I’m an ID clinical academic currently working on bacterial/viral confection in West Africa
This is a really useful insight that hopefully will guide how we prevent future spill overs
Looks like the link Bluesky has made doesn’t work - but clicking the link directly in the text is fine
It's fine on a phone but best read on a browser.
This project started life as a custom markdown template for our research group. The tutorial links to that package and has a section at the bottom on customising the logo and branding for your lab/group.
R markdown is an amazing way to share pre-publication findings with colleagues and collaborators.
If you use R but haven't taken advantage of markdown then I have a tutorial just for you: jackwgoodall.github.io/floreytemplate
It's new so I would love your feedback.
#IDsky #AcademicSky #episky
IMage showing vaccine vials, resarchers etc to illustrate the call for the Eurosurveillance annual theme 2025: "Vaccine-preventable diseases in humans — today's challenges and tomorrow's opportunities"
New to this place 🦋, moving on from the other place
Here to provide you #EpiSky #IDsky updates from Europe's weekly, peer-reviewed scientific journal on infectious disease epidemiology, prevention & control
#PublicHealth
Submit your papers now for our annual theme 2025 😷💉
bit.ly/annualtheme25
🧵Next week, you will see people using something called Benford's Law to try to prove election fraud.
⛔️These people are wrong⛔️
I am a scientist who has published on Benford's Law. Let me tell you what it is and why what they are doing is mathematically incorrect. 1/
(Key **players** this should say!)
I was lucky enough to work on the AMBITION trial (although had nothing to do with the design) and it has to be said that their motivation was to improve treatment options in low resource settings. This is just a happy bonus.
But PICC lines and hospitalisation are risky anywhere (especially if you have no immune system). This feels especially relevant to people how are surprisingly well with crypto but would be very vulnerable to nosocomial complications.
The design is very smart as it has hard fungal dynamic outcomes too. If it didn’t have this then you could easily argue that the risks/benefits of hospitalisation and long term IV access could be different in different countries.